Osteoarthritis Drugs Market: Global Industry Analysis and forecast (2022 – 2029)


Osteoarthritis Drugs Market size is expected to reach US$ 14.30 Bn. by year 2029 at a CAGR of 8.8% during the forecast period.

Osteoarthritis Drugs Market

To know about the Research Methodology :- Request Free Sample Report

Osteoarthritis Drugs Market Drivers and Restrains:

Osteoarthritis (OA), known as degenerative joint disease or degenerative arthritis, is the most commonly arising chronic condition that affects the joints and to severe joint pain and inability to easily move of the affected body parts. Osteoarthritis can be treated by several treatments, which include exercise for reducing joint pain, and pain medications. Pain medication includes drugs, such as paracetamol, naproxen, ibuprofen, etc. Currently, there is no cure for osteoarthritis, but the treatment is intended at managing the symptoms such as limited range of movement in a joint, affected joints may bulge after lengthy activity, clicking or a cracking sound after a joint bends, pain may also increase after activity or towards the end of the day.

The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.

The global osteoarthritis drugs market expected to witness significant growth rate owing to the rising geriatric population, increasing incidence of osteoarthritis disorders, and growing awareness of diseases like degenerative bone disease. For instance, According to the World health Organization (WHO), 9.6% of men and 18.0% of women aged over 60 years have indicative osteoarthritis worldwide. Among those 80% with osteoarthritis will have limitations in movement and 25% cannot perform their major daily activities of life. This high prevalence generates a requirement for OA pain drugs.

However, Lack of seriousness in treating arthritis differently than conditions like old age is restraining the market growth at global level. Loss of patent exclusivity of branded therapies, the side effects of the drugs, more awareness and promising drugs that may impulse the market growth during upcoming period. Additionally, there are many osteoarthritis research studies ongoing on cartilage (the lubricating surface in the joint). The work is being complete to re-grow the cartilage using stem cells treated with molecules to aid their growth. Hence, continuing research and rising government funding to provide new lucrative opportunities for the growth of the osteoarthritis drugs market.

Osteoarthritis Drugs Market Segmentation Analysis:

Base on the drugs class, the global osteoarthritis drugs market has been segmented into NSAIDs, opioids, viscosupplements, and corticosteroids. The Non-steroidal Anti-inflammatory Drugs (NSAIDs) is expected to grow at the largest CAGR of xx% during the forecast period. They are found to be the most commonly used drugs to ease pain, inflammation, and stiffness that come with arthritis, bursitis, and tendinitis. Therefore, NSAIDs have been an important drugs for the symptoms of osteoarthritis for a very long time. They are also cheap and often among the first medicines prescribed for people with achy joints.

Based on the distribution channel, the global osteoarthritis drugs market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment held a major share of the market in 2021, followed by retail pharmacies. The hospital pharmacies segment is projected to continue this trend during forecast period due to acceptance of advanced treatment options requiring hospitalization. The online pharmacies segment is likely to expand at a considerable CAGR of xx% during the near future, owing to easy availability of over the-counter drugs at home at a discounted price.

Osteoarthritis Drugs Market Regional Insights:

Geographically, the global osteoarthritis drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the osteoarthritis drugs market owing to high receiving of viscosupplementation agents in the U.S. and presence of key players in the region. One in every five adults in the U.S. has doctor diagnosed arthritis by according to the Centers for Disease Control and Prevention. Rising incidence of osteoarthritis leading to disability, demanding advanced therapies and disease modifying drugs, are driving the market in North America.

The market in Asia Pacific is likely to expand at a significantly high CAGR of xx% during the forecast period, due to improving health care infrastructure, rising investments in research and development in countries such as China and India, and high acceptance of viscosupplementation agents in Japan. Moreover, Japan is the second-largest market for viscosupplementation products after the U.S., which in turn is anticipated to further increase the market in Asia Pacific in the upcoming period.

A report covers the recent development in market for osteoarthritis drugs market i.e. In May 2017, Sanofi Inc. received the U.S. Food and Drug Administration (FDA) approval for Kevzara (sarilumab) injection, which aids in the treatment of rheumatoid arthritis in adults. In February 2014, Bioventus announced agreement with Galderma to gain access to DUROLANE, which is used in pain relief of joints in osteoarthritis. In December 2017, Flexion Therapeutics, Inc. announced acquisition of GeneQuine Biotherapeutics GmbH’s asset, GQ-203 (now known as FX201). It is a non-opioid therapeutic developed for symptomatic pain relief in knee osteoarthritis.

Osteoarthritis Drugs Market Competitive landscape

Major Key players operating in this market are Pfizer Inc., Horizon Pharma plc, Ferring B.V., Sanofi, Anika Therapeutics, Inc., Chugai Pharmaceutical Co., and Bioventus, Inc. Manufacturers in the osteoarthritis drugs are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

The objective of the report is to present comprehensive analysis of global osteoarthritis drugs market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers the all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region.

PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers.

The report also helps in understanding global osteoarthritis drugs market dynamics, structure by analyzing the market segments, and project the global osteoarthritis drugs market size. Clear representation of competitive analysis of key players by drug class, price, financial position, product portfolio, growth strategies, and regional presence in the global osteoarthritis drugs market make the report investor’s guide.

Osteoarthritis Drugs Market Scope: Inquire before buying


Osteoarthritis Drugs Market, by Drug Class:

• NSAIDs
• Opioids
• Viscosupplements
• Corticosteroids

Osteoarthritis Drugs Market, by Route of Administration:

• Oral
• Parenteral
• Topical

Osteoarthritis Drugs Market, by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Osteoarthritis Drugs Market, by Dosage Forms:

• Solid
• Liquid
• Semi-solid

Osteoarthritis Drugs Market, by Region:

• Asia Pacific
• North America
• Europe
• Latin America
• Middle East Africa

Osteoarthritis Drugs Market, Key Players:

• Bayer Healthcare
• Lifecore Biomedical LLC
• Merck Serono
• Pfizer Consumer Healthcare
• Iroko Pharmaceuticals
• Sanofi SA
• Smith & Nephew PLC
• Zimmer Biomet
• Abbott Laboratories
• Johnson & Johnson
• Novartis AG
• Pfizer Inc.
• AbbVie Inc.
• Eli Lilly and Company
• ABIOGEN PHARMA S.p.A
• Horizon Pharma plc.
• Ferring B.V.
• Merck Sharp & Dohme Corp.
• Medivir
• Bioventus, Inc.
• Flexion Therapeutics, Inc.
• Regeneron, and
• GlaxoSmithKline Plc.

Frequently Asked Questions:

1. Which region has the largest share in Global Osteoarthritis Drugs Market?
Ans: North America region holds the highest share in 2021.

2. What is the growth rate of Global Osteoarthritis Drugs Market?
Ans: The Global Osteoarthritis Drugs Market is growing at a CAGR of 8.8% during forecasting period 2022-2029.

3. What is scope of the Global Osteoarthritis Drugs market report?
Ans: Global Osteoarthritis Drugs Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Osteoarthritis Drugs market?
Ans: The important key players in the Global Osteoarthritis Drugs Market are – Bayer Healthcare, Lifecore Biomedical LLC, Merck Serono, Pfizer Consumer Healthcare, Iroko Pharmaceuticals, Sanofi SA, Smith & Nephew PLC, Zimmer Biomet, Abbott Laboratories, Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Eli Lilly and Company, ABIOGEN PHARMA S.p.A, Horizon Pharma plc., Ferring B.V., Merck Sharp & Dohme Corp., Medivir, Bioventus, Inc., Flexion Therapeutics, Inc., Regeneron, and, and GlaxoSmithKline Plc.

5. What is the study period of this market?
Ans: The Global Osteoarthritis Drugs Market is studied from 2021 to 2029. 




Global Osteoarthritis Drugs Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Global Osteoarthritis Drugs Market Size, by Market Value (US$ Mn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators
6. Global Osteoarthritis Drugs Market Analysis and Forecast
6.1. Global Osteoarthritis Drugs Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Global Osteoarthritis Drugs Market Analysis and Forecast, by Drug Class
7.1. Introduction and Definition
7.2. Key Findings
7.3. Global Osteoarthritis Drugs Market Value Share Analysis, by Drug Class
7.4. Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Drug Class
7.5. Global Osteoarthritis Drugs Market Analysis, by Drug Class
7.6. Global Osteoarthritis Drugs Market Attractiveness Analysis, by Drug Class

8. Global Osteoarthritis Drugs Market Analysis and Forecast, by Route of Administration
8.1. Introduction and Definition
8.2. Key Findings
8.3. Global Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration
8.4. Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Route of Administration
8.5. Global Osteoarthritis Drugs Market Analysis, by Route of Administration
8.6. Global Osteoarthritis Drugs Market Attractiveness Analysis, by Route of Administration

9. Global Osteoarthritis Drugs Market Analysis and Forecast, by Distribution Channel
9.1. Introduction and Definition
9.2. Key Findings
9.3. Global Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel
9.4. Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Distribution Channel
9.5. Global Osteoarthritis Drugs Market Analysis, by Distribution Channel
9.6. Global Osteoarthritis Drugs Market Attractiveness Analysis, by Distribution Channel

10. Global Osteoarthritis Drugs Market Analysis and Forecast, by Dosage Forms
10.1. Introduction and Definition
10.2. Key Findings
10.3. Global Osteoarthritis Drugs Market Value Share Analysis, by Dosage Forms
10.4. Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Dosage Forms
10.5. Global Osteoarthritis Drugs Market Analysis, by Dosage Forms
10.6. Global Osteoarthritis Drugs Market Attractiveness Analysis, by Dosage Forms

11. Global Osteoarthritis Drugs Market Analysis, by Region
11.1. Global Osteoarthritis Drugs Market Value Share Analysis, by Region
11.2. Global Osteoarthritis Drugs Market Size (US$ Mn) Forecast, by Region
11.3. Global Osteoarthritis Drugs Market Attractiveness Analysis, by Region

12. North America Osteoarthritis Drugs Market Analysis
12.1. Key Findings
12.2. North America Osteoarthritis Drugs Market Overview
12.3. North America Osteoarthritis Drugs Market Value Share Analysis, by Drug Class
12.4. North America Osteoarthritis Drugs Market Forecast, by Drug Class
12.4.1. NSAIDs
12.4.2. Opioids
12.4.3. Viscosupplements
12.4.4. Corticosteroids
12.5. North America Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration
12.6. North America Osteoarthritis Drugs Market Forecast, by Route of Administration
12.6.1. Oral
12.6.2. Parenteral
12.6.3. Topical
12.7. North America Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel
12.8. North America Osteoarthritis Drugs Market Forecast, by Distribution Channel
12.8.1. Hospital Pharmacies
12.8.2. Retail Pharmacies
12.8.3. Online Pharmacies
12.9. North America Osteoarthritis Drugs Market Value Share Analysis, by Dosage Forms
12.10. North America Osteoarthritis Drugs Market Forecast, by Dosage Forms
12.10.1. Solid
12.10.2. Liquid
12.10.3. Semi-solid
12.11. North America Osteoarthritis Drugs Market Value Share Analysis, by Country
12.12. North America Osteoarthritis Drugs Market Forecast, by Country
12.12.1. U.S.
12.12.2. Canada
12.13. North America Osteoarthritis Drugs Market Analysis, by Country
12.14. U.S. Osteoarthritis Drugs Market Forecast, by Drug Class
12.14.1. NSAIDs
12.14.2. Opioids
12.14.3. Viscosupplements
12.14.4. Corticosteroids
12.15. U.S. Osteoarthritis Drugs Market Forecast, by Route of Administration
12.15.1. Oral
12.15.2. Parenteral
12.15.3. Topical
12.16. U.S. Osteoarthritis Drugs Market Forecast, by Distribution Channel
12.16.1. Hospital Pharmacies
12.16.2. Retail Pharmacies
12.16.3. Online Pharmacies
12.17. U.S. Osteoarthritis Drugs Market Forecast, by Dosage Forms
12.17.1. Solid
12.17.2. Liquid
12.17.3. Semi-solid
12.18. Canada Osteoarthritis Drugs Market Forecast, by Drug Class
12.18.1. NSAIDs
12.18.2. Opioids
12.18.3. Viscosupplements
12.18.4. Corticosteroids
12.19. Canada Osteoarthritis Drugs Market Forecast, by Route of Administration
12.19.1. Oral
12.19.2. Parenteral
12.19.3. Topical
12.20. Canada Osteoarthritis Drugs Market Forecast, by Distribution Channel
12.20.1. Hospital Pharmacies
12.20.2. Retail Pharmacies
12.20.3. Online Pharmacies
12.21. Canada Osteoarthritis Drugs Market Forecast, by Dosage Forms
12.21.1. Solid
12.21.2. Liquid
12.21.3. Semi-solid
12.22. North America Osteoarthritis Drugs Market Attractiveness Analysis
12.22.1. By Drug Class
12.22.2. By Route of Administration
12.22.3. By Distribution Channel
12.22.4. By Dosage Forms
12.23. PEST Analysis
12.24. Key Trends
12.25. Key Developments

13. Europe Osteoarthritis Drugs Market Analysis
13.1. Key Findings
13.2. Europe Osteoarthritis Drugs Market Overview
13.3. Europe Osteoarthritis Drugs Market Value Share Analysis, by Drug Class
13.4. Europe Osteoarthritis Drugs Market Forecast, by Drug Class
13.4.1. NSAIDs
13.4.2. Opioids
13.4.3. Viscosupplements
13.4.4. Corticosteroids
13.5. Europe Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration
13.6. Europe Osteoarthritis Drugs Market Forecast, by Route of Administration
13.6.1. Oral
13.6.2. Parenteral
13.6.3. Topical
13.7. Europe Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel
13.8. Europe Osteoarthritis Drugs Market Forecast, by Distribution Channel
13.8.1. Hospital Pharmacies
13.8.2. Retail Pharmacies
13.8.3. Online Pharmacies
13.9. Europe Osteoarthritis Drugs Market Value Share Analysis, by Dosage Forms
13.10. Europe Osteoarthritis Drugs Market Forecast, by Dosage Forms
13.10.1. Solid
13.10.2. Liquid
13.10.3. Semi-solid
13.11. Europe Osteoarthritis Drugs Market Value Share Analysis, by Country
13.12. Europe Osteoarthritis Drugs Market Forecast, by Country
13.12.1. Germany
13.12.2. U.K.
13.12.3. France
13.12.4. Italy
13.12.5. Spain
13.12.6. Rest of Europe
13.13. Europe Osteoarthritis Drugs Market Analysis, by Country
13.14. Germany Osteoarthritis Drugs Market Forecast, by Drug Class
13.14.1. NSAIDs
13.14.2. Opioids
13.14.3. Viscosupplements
13.14.4. Corticosteroids
13.15. Germany Osteoarthritis Drugs Market Forecast, by Route of Administration
13.15.1. Oral
13.15.2. Parenteral
13.15.3. Topical
13.16. Germany Osteoarthritis Drugs Market Forecast, by Distribution Channel
13.16.1. Hospital Pharmacies
13.16.2. Retail Pharmacies
13.16.3. Online Pharmacies
13.17. Germany Osteoarthritis Drugs Market Forecast, by Dosage Forms
13.17.1. Solid
13.17.2. Liquid
13.17.3. Semi-solid
13.18. U.K. Osteoarthritis Drugs Market Forecast, by Drug Class
13.18.1. NSAIDs
13.18.2. Opioids
13.18.3. Viscosupplements
13.18.4. Corticosteroids
13.19. U.K. Osteoarthritis Drugs Market Forecast, by Route of Administration
13.19.1. Oral
13.19.2. Parenteral
13.19.3. Topical
13.20. U.K. Osteoarthritis Drugs Market Forecast, by Distribution Channel
13.20.1. Hospital Pharmacies
13.20.2. Retail Pharmacies
13.20.3. Online Pharmacies
13.21. U.K. Osteoarthritis Drugs Market Forecast, by Dosage Forms
13.21.1. Solid
13.21.2. Liquid
13.21.3. Semi-solid
13.22. France Osteoarthritis Drugs Market Forecast, by Drug Class
13.22.1. NSAIDs
13.22.2. Opioids
13.22.3. Viscosupplements
13.22.4. Corticosteroids
13.23. France Osteoarthritis Drugs Market Forecast, by Route of Administration
13.23.1. Oral
13.23.2. Parenteral
13.23.3. Topical
13.24. France Osteoarthritis Drugs Market Forecast, by Distribution Channel
13.24.1. Hospital Pharmacies
13.24.2. Retail Pharmacies
13.24.3. Online Pharmacies
13.25. France Osteoarthritis Drugs Market Forecast, by Dosage Forms
13.25.1. Solid
13.25.2. Liquid
13.25.3. Semi-solid
13.26. Italy Osteoarthritis Drugs Market Forecast, by Drug Class
13.26.1. NSAIDs
13.26.2. Opioids
13.26.3. Viscosupplements
13.26.4. Corticosteroids
13.27. Italy Osteoarthritis Drugs Market Forecast, by Route of Administration
13.27.1. Oral
13.27.2. Parenteral
13.27.3. Topical
13.28. Italy Osteoarthritis Drugs Market Forecast, by Distribution Channel
13.28.1. Hospital Pharmacies
13.28.2. Retail Pharmacies
13.28.3. Online Pharmacies
13.29. Italy Osteoarthritis Drugs Market Forecast, by Dosage Forms
13.29.1. Solid
13.29.2. Liquid
13.29.3. Semi-solid
13.30. Spain Osteoarthritis Drugs Market Forecast, by Drug Class
13.30.1. NSAIDs
13.30.2. Opioids
13.30.3. Viscosupplements
13.30.4. Corticosteroids
13.31. Spain Osteoarthritis Drugs Market Forecast, by Route of Administration
13.31.1. Oral
13.31.2. Parenteral
13.31.3. Topical
13.32. Spain Osteoarthritis Drugs Market Forecast, by Distribution Channel
13.32.1. Hospital Pharmacies
13.32.2. Retail Pharmacies
13.32.3. Online Pharmacies
13.33. Spain Osteoarthritis Drugs Market Forecast, by Dosage Forms
13.33.1. Solid
13.33.2. Liquid
13.33.3. Semi-solid
13.34. Rest of Europe Osteoarthritis Drugs Market Forecast, by Drug Class
13.34.1. NSAIDs
13.34.2. Opioids
13.34.3. Viscosupplements
13.34.4. Corticosteroids
13.35. Rest of Europe Osteoarthritis Drugs Market Forecast, by Route of Administration
13.35.1. Oral
13.35.2. Parenteral
13.35.3. Topical
13.36. Rest of Europe Osteoarthritis Drugs Market Forecast, by Distribution Channel
13.36.1. Hospital Pharmacies
13.36.2. Retail Pharmacies
13.36.3. Online Pharmacies
13.37. Rest Of Europe Osteoarthritis Drugs Market Forecast, by Dosage Forms
13.37.1. Solid
13.37.2. Liquid
13.37.3. Semi-solid
13.38. Europe Osteoarthritis Drugs Market Attractiveness Analysis
13.38.1. By Drug Class
13.38.2. By Route of Administration
13.38.3. By Distribution Channel
13.38.4. By Dosage Forms
13.39. PEST Analysis
13.40. Key Trends
13.41. Key Developments

14. Asia Pacific Osteoarthritis Drugs Market Analysis
14.1. Key Findings
14.2. Asia Pacific Osteoarthritis Drugs Market Overview
14.3. Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Drug Class
14.4. Asia Pacific Osteoarthritis Drugs Market Forecast, by Drug Class
14.4.1. NSAIDs
14.4.2. Opioids
14.4.3. Viscosupplements
14.4.4. Corticosteroids
14.5. Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration
14.6. Asia Pacific Osteoarthritis Drugs Market Forecast, by Route of Administration
14.6.1. Oral
14.6.2. Parenteral
14.6.3. Topical
14.7. Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel
14.8. Asia Pacific Osteoarthritis Drugs Market Forecast, by Distribution Channel
14.8.1. Hospital Pharmacies
14.8.2. Retail Pharmacies
14.8.3. Online Pharmacies
14.9. Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Dosage Forms
14.10. Asia Pacific Osteoarthritis Drugs Market Forecast, by Dosage Forms
14.10.1. Solid
14.10.2. Liquid
14.10.3. Semi-solid
14.11. Asia Pacific Osteoarthritis Drugs Market Value Share Analysis, by Country
14.12. Asia Pacific Osteoarthritis Drugs Market Forecast, by Country
14.12.1. China
14.12.2. India
14.12.3. Japan
14.12.4. ASEAN
14.12.5. Rest of Asia Pacific
14.13. Asia Pacific Osteoarthritis Drugs Market Analysis, by Country
14.14. China Osteoarthritis Drugs Market Forecast, by Drug Class
14.14.1. NSAIDs
14.14.2. Opioids
14.14.3. Viscosupplements
14.14.4. Corticosteroids
14.15. China Osteoarthritis Drugs Market Forecast, by Route of Administration
14.15.1. Oral
14.15.2. Parenteral
14.15.3. Topical
14.16. China Osteoarthritis Drugs Market Forecast, by Distribution Channel
14.16.1. Hospital Pharmacies
14.16.2. Retail Pharmacies
14.16.3. Online Pharmacies
14.17. China Osteoarthritis Drugs Market Forecast, by Dosage Forms
14.17.1. Solid
14.17.2. Liquid
14.17.3. Semi-solid
14.18. India Osteoarthritis Drugs Market Forecast, by Drug Class
14.18.1. NSAIDs
14.18.2. Opioids
14.18.3. Viscosupplements
14.18.4. Corticosteroids
14.19. India Osteoarthritis Drugs Market Forecast, by Route of Administration
14.19.1. Oral
14.19.2. Parenteral
14.19.3. Topical
14.20. India Osteoarthritis Drugs Market Forecast, by Distribution Channel
14.20.1. Hospital Pharmacies
14.20.2. Retail Pharmacies
14.20.3. Online Pharmacies
14.21. India Osteoarthritis Drugs Market Forecast, by Dosage Forms
14.21.1. Solid
14.21.2. Liquid
14.21.3. Semi-solid
14.22. Japan Osteoarthritis Drugs Market Forecast, by Drug Class
14.22.1. NSAIDs
14.22.2. Opioids
14.22.3. Viscosupplements
14.22.4. Corticosteroids
14.23. Japan Osteoarthritis Drugs Market Forecast, by Route of Administration
14.23.1. Oral
14.23.2. Parenteral
14.23.3. Topical
14.24. Japan Osteoarthritis Drugs Market Forecast, by Distribution Channel
14.24.1. Hospital Pharmacies
14.24.2. Retail Pharmacies
14.24.3. Online Pharmacies
14.25. Japan Osteoarthritis Drugs Market Forecast, by Dosage Forms
14.25.1. Solid
14.25.2. Liquid
14.25.3. Semi-solid
14.26. ASEAN Osteoarthritis Drugs Market Forecast, by Drug Class
14.26.1. NSAIDs
14.26.2. Opioids
14.26.3. Viscosupplements
14.26.4. Corticosteroids
14.27. ASEAN Osteoarthritis Drugs Market Forecast, by Route of Administration
14.27.1. Oral
14.27.2. Parenteral
14.27.3. Topical
14.28. ASEAN Osteoarthritis Drugs Market Forecast, by Distribution Channel
14.28.1. Hospital Pharmacies
14.28.2. Retail Pharmacies
14.28.3. Online Pharmacies
14.29. ASEAN Osteoarthritis Drugs Market Forecast, by Dosage Forms
14.29.1. Solid
14.29.2. Liquid
14.29.3. Semi-solid
14.30. Rest of Asia Pacific Osteoarthritis Drugs Market Forecast, by Drug Class
14.30.1. NSAIDs
14.30.2. Opioids
14.30.3. Viscosupplements
14.30.4. Corticosteroids
14.31. Rest of Asia Pacific Osteoarthritis Drugs Market Forecast, by Route of Administration
14.31.1. Oral
14.31.2. Parenteral
14.31.3. Topical
14.32. Rest of Asia Pacific Osteoarthritis Drugs Market Forecast, by Distribution Channel
14.32.1. Hospital Pharmacies
14.32.2. Retail Pharmacies
14.32.3. Online Pharmacies
14.33. Rest of Asia Pacific Osteoarthritis Drugs Market Forecast, by Dosage Forms
14.33.1. Solid
14.33.2. Liquid
14.33.3. Semi-solid
14.34. Asia Pacific Osteoarthritis Drugs Market Attractiveness Analysis
14.34.1. By Drug Class
14.34.2. By Route of Administration
14.34.3. By Distribution Channel
14.34.4. By Dosage Forms
14.35. PEST Analysis
14.36. Key Trends
14.37. Key Developments

15. Middle East & Africa Osteoarthritis Drugs Market Analysis
15.1. Key Findings
15.2. Middle East & Africa Osteoarthritis Drugs Market Overview
15.3. Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Drug Class
15.4. Middle East & Africa Osteoarthritis Drugs Market Forecast, by Drug Class
15.4.1. NSAIDs
15.4.2. Opioids
15.4.3. Viscosupplements
15.4.4. Corticosteroids
15.5. Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration
15.6. Middle East & Africa Osteoarthritis Drugs Market Forecast, by Route of Administration
15.6.1. Oral
15.6.2. Parenteral
15.6.3. Topical
15.7. Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel
15.8. Middle East & Africa Osteoarthritis Drugs Market Forecast, by Distribution Channel
15.8.1. Hospital Pharmacies
15.8.2. Retail Pharmacies
15.8.3. Online Pharmacies
15.9. Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Dosage Forms
15.10. Middle East & Africa Osteoarthritis Drugs Market Forecast, by Dosage Forms
15.10.1. Solid
15.10.2. Liquid
15.10.3. Semi-solid
15.11. Middle East & Africa Osteoarthritis Drugs Market Value Share Analysis, by Country
15.12. Middle East & Africa Osteoarthritis Drugs Market Forecast, by Country
15.12.1. GCC
15.12.2. South Africa
15.12.3. Rest of Middle East & Africa
15.13. Middle East & Africa Osteoarthritis Drugs Market Analysis, by Country
15.14. GCC Osteoarthritis Drugs Market Forecast, by Drug Class
15.14.1. NSAIDs
15.14.2. Opioids
15.14.3. Viscosupplements
15.14.4. Corticosteroids
15.15. GCC Osteoarthritis Drugs Market Forecast, by Route of Administration
15.15.1. Oral
15.15.2. Parenteral
15.15.3. Topical
15.16. GCC Osteoarthritis Drugs Market Forecast, by Distribution Channel
15.16.1. Hospital Pharmacies
15.16.2. Retail Pharmacies
15.16.3. Online Pharmacies
15.17. GCC Osteoarthritis Drugs Market Forecast, by Dosage Forms
15.17.1. Solid
15.17.2. Liquid
15.17.3. Semi-solid
15.18. South Africa Osteoarthritis Drugs Market Forecast, by Drug Class
15.18.1. NSAIDs
15.18.2. Opioids
15.18.3. Viscosupplements
15.18.4. Corticosteroids
15.19. South Africa Osteoarthritis Drugs Market Forecast, by Route of Administration
15.19.1. Oral
15.19.2. Parenteral
15.19.3. Topical
15.20. South Africa Osteoarthritis Drugs Market Forecast, by Distribution Channel
15.20.1. Hospital Pharmacies
15.20.2. Retail Pharmacies
15.20.3. Online Pharmacies
15.21. South Africa Osteoarthritis Drugs Market Forecast, by Dosage Forms
15.21.1. Solid
15.21.2. Liquid
15.21.3. Semi-solid
15.22. Rest of Middle East & Africa Osteoarthritis Drugs Market Forecast, by Drug Class
15.22.1. NSAIDs
15.22.2. Opioids
15.22.3. Viscosupplements
15.22.4. Corticosteroids
15.23. Rest of Middle East & Africa Osteoarthritis Drugs Market Forecast, by Route of Administration
15.23.1. Oral
15.23.2. Parenteral
15.23.3. Topical
15.24. Rest of Middle East & Africa Osteoarthritis Drugs Market Forecast, by Distribution Channel
15.24.1. Hospital Pharmacies
15.24.2. Retail Pharmacies
15.24.3. Online Pharmacies
15.25. Rest of Middle East & Africa Osteoarthritis Drugs Market Forecast, by Dosage Forms
15.25.1. Solid
15.25.2. Liquid
15.25.3. Semi-solid
15.26. Middle East & Africa Osteoarthritis Drugs Market Attractiveness Analysis
15.26.1. By Drug Class
15.26.2. By Route of Administration
15.26.3. By Distribution Channel
15.26.4. By Dosage Forms
15.27. PEST Analysis
15.28. Key Trends
15.29. Key Developments

16. South America Osteoarthritis Drugs Market Analysis
16.1. Key Findings
16.2. South America Osteoarthritis Drugs Market Overview
16.3. South America Osteoarthritis Drugs Market Value Share Analysis, by Drug Class
16.4. South America Osteoarthritis Drugs Market Forecast, by Drug Class
16.4.1. NSAIDs
16.4.2. Opioids
16.4.3. Viscosupplements
16.4.4. Corticosteroids
16.5. South America Osteoarthritis Drugs Market Value Share Analysis, by Route of Administration
16.6. South America Osteoarthritis Drugs Market Forecast, by Route of Administration
16.6.1. Oral
16.6.2. Parenteral
16.6.3. Topical
16.7. South America Osteoarthritis Drugs Market Value Share Analysis, by Distribution Channel
16.8. South America Osteoarthritis Drugs Market Forecast, by Distribution Channel
16.8.1. Hospital Pharmacies
16.8.2. Retail Pharmacies
16.8.3. Online Pharmacies
16.9. South America Osteoarthritis Drugs Market Value Share Analysis, by Dosage Forms
16.10. South America Osteoarthritis Drugs Market Forecast, by Dosage Forms
16.10.1. Solid
16.10.2. Liquid
16.10.3. Semi-solid
16.11. South America Osteoarthritis Drugs Market Value Share Analysis, by Country
16.12. South America Osteoarthritis Drugs Market Forecast, by Country
16.12.1. Brazil
16.12.2. Mexico
16.12.3. Rest of South America
16.13. South America Osteoarthritis Drugs Market Analysis, by Country
16.14. Brazil Osteoarthritis Drugs Market Forecast, by Drug Class
16.14.1. NSAIDs
16.14.2. Opioids
16.14.3. Viscosupplements
16.14.4. Corticosteroids
16.15. Brazil Osteoarthritis Drugs Market Forecast, by Route of Administration
16.15.1. Oral
16.15.2. Parenteral
16.15.3. Topical
16.16. Brazil Osteoarthritis Drugs Market Forecast, by Distribution Channel
16.16.1. Hospital Pharmacies
16.16.2. Retail Pharmacies
16.16.3. Online Pharmacies
16.17. Brazil Osteoarthritis Drugs Market Forecast, by Dosage Forms
16.17.1. Solid
16.17.2. Liquid
16.17.3. Semi-solid
16.18. Mexico Osteoarthritis Drugs Market Forecast, by Drug Class
16.18.1. NSAIDs
16.18.2. Opioids
16.18.3. Viscosupplements
16.18.4. Corticosteroids
16.19. Mexico Osteoarthritis Drugs Market Forecast, by Route of Administration
16.19.1. Oral
16.19.2. Parenteral
16.19.3. Topical
16.20. Mexico Osteoarthritis Drugs Market Forecast, by Distribution Channel
16.20.1. Hospital Pharmacies
16.20.2. Retail Pharmacies
16.20.3. Online Pharmacies
16.21. Mexico Osteoarthritis Drugs Market Forecast, by Dosage Forms
16.21.1. Solid
16.21.2. Liquid
16.21.3. Semi-solid
16.22. Rest of South America Osteoarthritis Drugs Market Forecast, by Drug Class
16.22.1. NSAIDs
16.22.2. Opioids
16.22.3. Viscosupplements
16.22.4. Corticosteroids
16.23. Rest of South America Osteoarthritis Drugs Market Forecast, by Route of Administration
16.23.1. Oral
16.23.2. Parenteral
16.23.3. Topical
16.24. Rest of South America Osteoarthritis Drugs Market Forecast, by Distribution Channel
16.24.1. Hospital Pharmacies
16.24.2. Retail Pharmacies
16.24.3. Online Pharmacies
16.25. Rest of South America Osteoarthritis Drugs Market Forecast, by Dosage Forms
16.25.1. Solid
16.25.2. Liquid
16.25.3. Semi-solid
16.26. South America Osteoarthritis Drugs Market Attractiveness Analysis
16.26.1. By Drug Class
16.26.2. By Route of Administration
16.26.3. By Distribution Channel
16.26.4. By Dosage Forms
16.27. PEST Analysis
16.28. Key Trends
16.29. Key Developments

17. Company Profiles
17.1. Market Share Analysis, by Company
17.2. Competition Matrix
17.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
17.2.2. New Product Launches and Product Enhancements
17.2.3. Market Consolidation
17.2.3.1. M&A by Regions, Investment and Applications
17.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
17.3. Company Profiles: Key Players
17.3.1. Bayer Healthcare
17.3.1.1. Company Overview
17.3.1.2. Financial Overview
17.3.1.3. Product Portfolio
17.3.1.4. Business Strategy
17.3.1.5. Recent Developments
17.3.1.6. Company Footprint
17.3.2. Lifecore Biomedical LLC
17.3.3. Merck Serono
17.3.4. Pfizer Consumer Healthcare
17.3.5. Iroko Pharmaceuticals
17.3.6. Sanofi SA
17.3.7. Smith & Nephew PLC
17.3.8. Zimmer Biomet
17.3.9. Abbott Laboratories
17.3.10. Johnson & Johnson
17.3.11. Novartis AG
17.3.12. Pfizer Inc
17.3.13. AbbVie Inc
17.3.14. Eli Lilly and CompanyBG
17.3.15. ABIOGEN PHARMA S.p.A
17.3.16. Horizon Pharma plc.
17.3.17. Ferring B.V.
17.3.18. Merck Sharp & Dohme Corp.
17.3.19. Medivir
17.3.20. Bioventus, Inc.
17.3.21. Flexion Therapeutics, Inc.
17.3.22. Regeneron, and
17.3.23. GlaxoSmithKline Plc.

18. Primary Key Insights
  • INQUIRE BEFORE BUYING